Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Antiretroviral Therapy News
Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV TreatmentA single-tablet regimen of bictegravir, emtricitabine and tenofovir alafenamide is noninferior to regimens of dolutegravir coformulated with emtricitabine and tenofovir alafenamide or with abacavir and lamivudine for the initial treatment of HIV-1 infection, according to results from two randomized phase 3 trials.
Reuters Health Information, June 7, 2019
Gilead to Donate Truvada to CDC to Help With HIV PrEP in US While the Trump administration praised the donation, activists maintained their call for a reduction in the cost of the antiviral treatment, now pegged at more than $20,000 a year.
